Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora, Paul Martin; Glatzer, Markus; De Ruysscher, Dirk; Faivre-Finn, Corinne; Belderbos, José; Besse, Benjamin; Blackhall, Fiona; Califano, Raffaele; Cappuzzo, Federico; de Marinis, Filippo; Dziadiuszko, Rafal; Felip, Enriqueta; Früh, Martin; Garrido, Pilar; Le Pechoux, Cecile; McDonald, Fiona; Nestle, Ursula; Novello, Silvia; Brien, Mary O'; Paz Ares, Luis; ... (2019). Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and oncology, 135, pp. 74-77. Elsevier 10.1016/j.radonc.2019.02.010

[img] Text
1-s2.0-S0167814019300775-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (497kB) | Request a copy

BACKGROUND

The role of consolidative thoracic radiotherapy (TRT) in stage IV small cell lung cancer (SCLC) is not uniformly accepted.

METHODS

We obtained a list of 13 European medical oncologists from the International Association for the Study of Lung Cancer (IASLC) and 13 European radiation oncologists from the European Society for Therapeutic Radiation Oncology (ESTRO). The strategies in decision making for TRT in stage IV SCLC were collected. Decision trees were created representing these strategies. Frequencies of recommending TRT were analysed for various parameter combinations based on the objective consensus methodology.

RESULTS

The factors associated with the recommendation for TRT included fitness of the patient, limited extrathoracic tumour burden, initial bulky thoracic disease and response to chemotherapy. The highest consensus for TRT was in fit patients with limited extrathoracic tumour burden and initial bulky disease with either a complete extrathoracic response or partial thoracic response (92% recommend TRT). For these patients the recommendations were the same for medical and radiation oncologists. In the setting of partial response (intra- and extra-thoracically) without initial bulky thoracic disease radiation oncologists were more likely to recommend TRT than medical oncologists. For unfit patients or for patients with poor overall response to chemotherapy, the majority did not recommend TRT.

CONCLUSION

European radiation and medical oncologists specializing in lung cancer recommend TRT in selected patients with stage IV SCLC and restrict its use primarily to fit patients who responded to chemotherapy with limited extrathoracic tumour burden.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Putora, Paul Martin and Glatzer, Markus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0167-8140

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

17 Jul 2019 13:58

Last Modified:

24 Oct 2019 23:20

Publisher DOI:

10.1016/j.radonc.2019.02.010

PubMed ID:

31015173

Uncontrolled Keywords:

ESTRO Expert opinion IASLC Small cell lung cancer Stage IV Thoracic radiotherapy

BORIS DOI:

10.7892/boris.130391

URI:

https://boris.unibe.ch/id/eprint/130391

Actions (login required)

Edit item Edit item
Provide Feedback